Somnics, Inc. announced that the company has received Korea Medical Device Registration and Approval（KFDA）for iNAP® One Sleep Therapy System, and the company joins forces with LMT Korea Co. Ltd., looking forward to launching the product in the second half of 2022. LMT Korea is one of the leading sleep respiratory diagnostic and treatment equipment providers in South Korea and the exclusive Korea distributor of Lowenstein respirators from Germany. With its comprehensive service coverage and close collaboration with more than 200 medical institutions, LMT has a high market share of CPAP devices in Korea.
“Demand for Sleep Tech services has increased at a rapid pace. ” said Eric, the Vice President of Somnics. “According to the research of NHIS Korea, the medical expenditure for sleep disorders grows at a rate of 25.2% from 2016 to 2020. Therefore, there is a considerable potential for the market.”
iNAP® is a new, patient-preferred, non-surgical device for the treatment of Obstructive Sleep Apnea (OSA) in adults of all severities-mild, moderate, and severe. With the mobile App and cloud-based platform, users can record the information of efficacy and get the treatment outcome for analysis and adjustment.
Hence, users of iNAP do not have to go to hospital for treatment, because the online communication between patients and health professionals has been established, especially during the Covid-19 pandemic.
iNAP® Sleep Therapy System has scored medical device licenses and entered the market in lots of areas, including Taiwan, USA, EU, UK, Australia, Hong Kong, Singapore, Thailand and Malaysia, etc. Somnics expects to expand its business portfolio in the East-Asia area and provide a more convenient and comprehensive sleep care treatment for OSA patients.
